Condition: Alcoholic Cirrhosis · Sponsor: Pharmicell Co., Ltd.
This phase III clinical trial is designed to evaluate the efficacy and safety of autologous Mesenchymal Stem Cells (MSC) injected hepatic artery.
This description comes directly from the study's public registry record.
JIYEOUN JEONG · 82-2-3496-0134 · jyjeong@pharmicell.com
Always discuss trial participation with your own doctor first.
| Soonchunhyang University Hospital | Bucheon-si, South Korea | Recruiting |
| Soonchunhyang University Hospital | Cheonan, South Korea | Recruiting |
| Gangwon National University Hospital | Chuncheon, South Korea | Recruiting |
| Hallym Univ. Medical Center | Chuncheon, South Korea | Recruiting |
| Gangneung Asan Hospital | Gangneung-si, South Korea | Recruiting |
| Eunpyeong St. Mary's Hospital | Seoul, South Korea | Recruiting |
| Korea University Anam Hospital | Seoul, South Korea | Recruiting |
| Seoul National University Hospital | Seoul, South Korea | Recruiting |
| Soonchunhyang University Hospital | Seoul, South Korea | Recruiting |
| Wonju Severance Christian Hospital | Wŏnju, South Korea | Recruiting |
| Yongin Severance Hospital | Yongin, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04689152